PARC DU TRIANGLE DE RECHERCHE – bioMason is getting new headquarters.
The Triangle biotech startup, which grows biocement materials by employing microorganisms, has secured a lease for a 30,335-square-foot office space at 2 Triangle Dr in Research Triangle Park.
The uptick: plans to hike its workforce headcount by 50 percent — from 50 to 75 by the end of the year.
“At bioMason, 2020 is one of our fastest growth years,” said Ginger Krieg Dosier, bioMASON’s President and CEO, in a statement.
bioMason moved to RTP in 2013 with a small office in the North Carolina Biotechnology Center, and a couple labs at First Flight Venture Center. After a short move to downtown Raleigh, the company relocated to RTP in 2016 to set up scaled pilot manufacturing and increased research and development activities in a 21,000-square-foot facility.
“Since 2016, we have outgrown our space and moved our headquarters to 2 Triangle Drive. We now have two facilities in RTP – only a 6-minute drive apart,” Dosier continued. “We are converting our 21,000-sf space into a fully dedicated production plant for our bioLITH tile, and growing product line.
“The decision to stay in RTP,” she added, “is a reflection on the prominence of the Park and its centralized location, as well as attracting world class talent.”
Located near the intersection of NC 54 and TW Alexander Dr, the headquarters sits on 12.15 acres and has approximately 15,000 square feet of laboratories and 14,000 square feet of office space.
bioMason said there is also the option to expand an additional 30,000 square feet. Amenities include 135 parking spaces, a mechanical room and a 150 KW emergency generator.
“Homegrown companies like bioMASON are what make Research Triangle Park so exceptional, and we are thrilled that they will continue to grow here in North Carolina,” said Scott Levitan, president and CEO of the Research Triangle Foundation, the organization tasked with stewardship of RTP’s land and amenities. “The ability of a local university graduate to not only bring their idea to life, but sustain and expand upon it right here in RTP, speaks volumes about our biotech ecosystem.”
Last December, bioMason launched a fundraising round aimed at securing $18 million. According to a SEC filing, it had already secured nearly $5 million from one investor.
Source originale de l’article : WRAL TechWire